Phytochemical Approach and Bioanalytical Strategy to Develop Chaperone-Based Medications

Bernd Kastenholz*
Aachen City Region, North Rhine-Westphalia, Eschweiler (Rhld.) 52249, Germany

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 178
Abstract HTML Views: 153
PDF Downloads: 66
Total Views/Downloads: 397
Unique Statistics:

Full-Text HTML Views: 109
Abstract HTML Views: 89
PDF Downloads: 48
Total Views/Downloads: 246

© Bernd Kastenholz; Licensee Bentham Open.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.

* Address correspondence to this author at the Aachen City Region, North Rhine-Westphalia, Eschweiler (Rhld.) 52249, Germany; E-mail:


Currently, no pharmaceuticals for the etiological treatment of degenerative protein-misfolding diseases (e.g., ALS, Alzheimer’s or prion diseases) are commercially available. In this technical note theoretical considerations and practical approaches concerning the development of chaperone-based medications from medicinal plants (e.g., Ginkgo biloba) are reviewed and discussed in detail. Phytochaperones and other agents isolated from medicinal plants are proposed to serve as the general basis of drug development in protein-misfolding diseases.

Keywords: : Phytochaperones, biofluids, Alzheimer’s disease, medicinal plant extracts, CCS, Ginkgo biloba, SOD, molecular farming, GPC, metal cofactors, homeostasis, QPNC-PAGE.